A real-life cohort of antifibrotic-treated non-IPF progressive pulmonary fibrosis patients

被引：0
|
作者：
Renner, A. [1 ,2 ]
Vertanen, E. [2 ]
Sutinen, E. [2 ,3 ,4 ]
Ainola, M. [2 ,3 ,4 ]
Myllaerniemi, M. [2 ,3 ,4 ]
Hollmen, M. [2 ,3 ,4 ]
机构：
[1] Med Univ Vienna, Pulmonol, Vienna, Austria
[2] Univ Helsinki, Individualized Drug Therapy Res Program, Fac Med, Helsinki, Finland
[3] Univ Helsinki, Helsinki, Finland
[4] Helsinki Univ Hosp, Dept Pulmonol, Helsinki, Finland
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2024年 / 136卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P63
引用
收藏
页码：S552 / S552
页数：1
相关论文
共 50 条
  • [31] SUBOPTIMAL DOSING AND DISCONTINUATION OF ANTIFIBROTIC AGENTS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Pimple, P.
    Nathan, S. D.
    Swigris, J. J.
    Olson, A. L.
    Shetty, S.
    VALUE IN HEALTH, 2024, 27 (06) : S314 - S314
  • [32] Outcomes of Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis (IPF) Patients with Circulating Autoantibodies
    Smith, A.
    Ding, G.
    Kropski, J.
    Mason, W.
    Lancaster, L. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [33] Rate Of Decline In FVC In Non-Ipf Pulmonary Fibrosis After Anti-Fibrotic Initiation
    Brown, J. C.
    Kraft, J.
    Vega-Olivo, M.
    Galli, J.
    Simpson, S.
    Criner, G. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [34] Baseline predictors of mortality in non-idiopathic pulmonary fibrosis interstitial lung disease (Non-IPF ILD)
    Sia, Leng Cheng
    Pang, Yong-Kek
    Wong, Chee-Kuan
    Sivakumar, Dinesh
    Chandran, Deevan Marc
    Soo, Chun Ian
    Ling, Shan-Yan
    Poh, Mau Ern
    Loh, Thian Chee
    Ibrahim, Nur Husna
    Munusamy, Vijayan
    Tan, Jiunn Liang
    Leong, Wai Ling
    RESPIROLOGY, 2024, 29 : 28 - 29
  • [35] Nintedanib in progressive Non-IPF-Pulmonary Fibrosis - A Subgroup Analysis
    Markart, Philipp
    PNEUMOLOGE, 2020, 17 (05): : 350 - 351
  • [36] Analyzing the variance in protein expression profiles between patients diagnosed with idiopathic pulmonary fibrosis (IPF) and those with non-IPF interstitial lung diseases (ILD)
    Yen, Tsai-Hung
    Fu, Pin-Kuei
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [37] Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study
    Tavanti, Laura
    De Magistris, Sara
    Romei, Chiara
    Perrone, Elisabetta
    Falaschi, Fabio
    Nieri, Dario
    Serradori, Massimiliano
    Celi, Alessandro
    Palla, Antonio
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [38] Real-life Data on the Safety and Tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) Patients: A Single-Centre Study
    Thong, L.
    Bowen, B.
    Henry, M. T.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 1) : S28 - S29
  • [39] Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)
    Guenther, Andreas
    Prasse, Antje
    Kreuter, Michael
    Neuser, Petra
    Rabe, Klaus
    Bonella, Francesco
    Bonnet, Reiner
    Grohe, Christian
    Held, Matthias
    Wilkens, Heinrike
    Hammerl, Peter
    Koschel, Dirk
    Blaas, Stefan
    Wirtz, Hubert
    Ficker, Joachim
    Neumeister, Wolfgang
    Schoenfeld, Nicolaus
    Claussen, Martin
    Kneidinger, Nikolaus
    Frankenberger, Marion
    Hummler, Simone
    Kahn, Nicolas
    Tello, Silke
    Freise, Julia
    Welte, Tobias
    Schade-Brittinger, Carmen
    Behr, Juergen
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [40] Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
    Kolonics-Farkas, Abigel M.
    Sterclova, Martina
    Mogulkoc, Nesrin
    Kus, Jan
    Hajkova, Marta
    Muller, Veronika
    Jovanovic, Dragana
    Tekavec-Trkanjec, Jasna
    Littnerova, Simona
    Hejduk, Karel
    Vasakova, Martina
    DRUG SAFETY, 2020, 43 (10) : 971 - 980
12345